Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.

Molecular medicine reports - 1 Jan 2015

Wang Zheling, Li Xiaofei, Shi Changhe, Zhang Min, Chen Ru, Wu Wei, Hou Qingshun, Ke Wei, Fan Tianli, Wen Zirong, Hao Xinjie, Qu Naifang

Abstract excerpt

Chronic hepatitis B (CHB) is one of the most common infectious disease worldwide and a leading cause of death. Hepatitis B surface antigen (HBsAg) has previously been proven to be a steady biomarker that may be used to predict clinical outcomes. The amount of circulating HBsAg has been reported to reflect the number of infected hepatocytes. An advantage of pegylated interferon alpha (peg-IFN-α) is that as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to Interferon-alpha

Share to Peptide Library

Share to Peptides

Share to Polyethylene Glycols

Source

Identifiers

PMID: 25324041
DOI: 10.3892/mmr.2014.2670

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.PMID 25324041Read ↗

Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferonSemantic proximity Read ↗

Hepatitis B core-related antigen: a novel biomarker for chronic hepatitis B treatment.Semantic proximity Read ↗

The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment.Semantic proximity Read ↗

Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection.Semantic proximity Read ↗

Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.Semantic proximity Read ↗

Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B.Semantic proximity Read ↗

A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.Semantic proximity Read ↗

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.Semantic proximity Read ↗

Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System.Semantic proximity Read ↗

Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers predicting HBsAg lossSemantic proximity Read ↗

Distinct seromarkers predict different milestones of chronic hepatitis B progression.Semantic proximity Read ↗

Multiple epitopes of hepatitis B virus surface antigen targeted by human plasma-derived immunoglobulins coincide with clinically observed escape mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.